Wellness Franchise Opportunities

PlanningApr, 29 2015

Pharma major Sun Pharma may spend $7bn on further acquisitions

Soon after acquiring its domestic rival Ranbaxy Laboratories, Pharma major Sun Pharmaceuticals Industries Ltd is keen to spend another $7 billion to satisfy its craving for more takeovers.

By Agencies

Emboldened by its takeover of domestic rival Ranbaxy Laboratories, India's leading Pharma company Sun Pharmaceuticals Industries Ltd is willing to spend as much as $7 billionon further acquisitions

The biggest deal till date at $3.2 billion, the Ranbaxy deal of Sun Pharma has given it sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.

As per the latest findings of leading business dailies, next on Sun Pharma's radar are US and European companies that develop bio-similars and cheaper copies of biotech drugs, which have become some of world's hottest selling medicines.

Dilip Shanghvi, who controls Sun Pharma with his scions and is India's second richest man as per the globally renowned Forbes magazine, feels the need for a ‘transformational acquisition’, but will be patient about finding the right candidate, said sources.

The Sun Pharma, which has a present market value of about $36 billion, is also interested in non-biotech complex generic medicines that offer better margins than the copied drugs specialised by Indian drugmakers.

Reportedly, the Pharma major is willing to look at either whole companies or acquire complex generics on their own, declining to be identified as they were not authorized to speak to the media on the matter.

In one potential near-term opportunity, Sun Pharma may emerge as a bidder for some drugs Teva Pharmaceutical Industries, the world's biggest generic drugmaker, will likely be required to divest if it is successful in its unsolicited $40 billion bid for rival Mylan.

With a cash balance of $1.5 billion and a debt-to-equity ratio of just 0.13, Sun Pharma would find it easy to take on debt to fund any large acquisition.
 

Related: Govt plans to roll out regulatory authority for National Health Assurance Mission

Click Here to add Comment
Please add your Comment
Rating
Sell Business 2017
Sell Franchise 2017

Newsletter Signup

Submit your email address to receive the latest updates on news & host of opportunities from Wellness India.

Video

Magazines & Books

Read the latest franchising magazines and books to get comprehensive and up-to-date information on leading franchise systems, trends and more.

Recommended For You

Newsletter Signup
Submit your email address to receive the latest updates on news & host of opportunities.
Well Ness India

Copyright © 2009 - 2017 Franchise India Holdings Ltd.

The information contained herein is of generic nature only, and Franchise India is not, by means of this website or any part thereof, rendering professional advice or services. Before making any decision or taking any action that might affect your finances or business, you should consult a qualified professional advisor. Your use of this website or any of its pages or links given, is at your own risk and you assume full responsibility and risk of loss resulting from your usage. With respect to use of the website, kindly visit www.franchiseindia.com/terms.